Cara Therapeutics: Scratching An Itch Left Unscratched | Latest News RSS feed

Cara Therapeutics: Scratching An Itch Left Unscratched - Latest News


Cara Therapeutics: Scratching An Itch Left Unscratched

CARA therapeutics wholly owns its proprietary kappa opioid-receptor agonist, KORSUVA/CR845, and is targeting several largely underserved markets. Several catalysts are expected throughout the next yea... read more

Here's Why Cara Therapeutics Rose 12.5% in August

That jumbled mess of scientific words essentially means Cara Therapeutics is developing a drug to treat itching that arises in some patients ... high-risk pharma stock that's best left to investors wi... read more

Small-Cap Snapshot: Cara Therapeutics lands licensing deal, Revlon appoints its first female CEO

Biotech Cara Therapeutics Inc (NASDAQ:CARA) was a top gainer following a licensing deal for its drug Korsuva, an injectable used to treat itching as a result of kidney dialysis. The Connecticut-based ... read more

Looking for another news?


Cara Therapeutics' (CARA) CEO Derek Chalmers on Q1 2015 Results - Earnings Call Transcript

Cara Therapeutics Inc. (NASDAQ ... of I.V. CR845 compared to placebo and reducing the intensity of itch in these patients over a two week dosing period. Endpoints include change in worse itching score... read more


Better Buy for 2018: Cara Therapeutics or Nektar Therapeutics?

But if Cara's shareholders are smiling, investors who owned Nektar Therapeutics (NASDAQ ... a couple of other late-stage studies evaluating the drug in treating pruritis (itching) in patients on dialy... read more

Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

Image source: Getty Images. Cara Therapeutics doesn't have any drugs to sell yet, but that could change following a couple of pivotal studies involving patients with chronic kidney disease who suffer ... read more

The Picture for Cara Therapeutics Just Got Clearer

Market Data Watchlists Industry News read more

Does Post-Op Success Make Cara Therapeutics a Buy Now?

Cara Therapeutics (NASDAQ: CARA ... an important option for a growing population of dialysis patients with nerve damage that leads to chronic itching. Does this stock look like a buy now that it's a b... read more

Here's Why Cara Therapeutics Rose 12.5% in August

That jumbled mess of scientific words essentially means Cara Therapeutics is developing a drug to treat itching that arises in some patients ... high-risk pharma stock that's best left to investors wi... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us